DPP4 and chronic kidney disease: Dipeptidylpeptidase-4 (DPP-4) inhibitors, commonly used in T2DM, may offeradditional benefits, such as reducing inflammation and uric acid levels.This study aimed to assess the impact of DPP-4 inhibitors on gout flarefrequency, serum uric acid (sUA) levels, and survival in patients withgout, T2DM, and CKD.